VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce results from Areta International laboratory in Italy. These results show dramatic increases in the production of monoclonal antibodies when AAGP™ is incorporated into the production cycle. Monoclonal antibodies are one of the fastest growing sectors of the pharmaceutical industry. This market is presently over $50-billion USD per year and growing rapidly. As a therapeutic, monoclonal antibodies do not cause the same side-effects of chemotherapy and radiation treatment.
